{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:59:41Z","timestamp":1778047181855,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00417-020-04924-0","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T06:02:21Z","timestamp":1606456941000},"page":"837-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical characteristics of super stable polypoidal choroidal vasculopathy after initial remission with anti-VEGF monotherapy"],"prefix":"10.1007","volume":"259","author":[{"given":"Seonghee","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae Min","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5932-8516","authenticated-orcid":false,"given":"Hyoung Jun","family":"Koh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"4924_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajo.2007.03.047","volume":"144","author":"I Maruko","year":"2007","unstructured":"Maruko I, Iida T, Saito M, Nagayama D, Saito K (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15\u201322.e12. https:\/\/doi.org\/10.1016\/j.ajo.2007.03.047","journal-title":"Am J Ophthalmol"},{"key":"4924_CR2","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1001\/archopht.121.10.1392","volume":"121","author":"K Sho","year":"2003","unstructured":"Sho K, Takahashi K, Yamada H, Wada M, Nagai Y, Otsuji T, Nishikawa M, Mitsuma Y, Yamazaki Y, Matsumura M, Uyama M (2003) Polypoidal choroidal vasculopathy: incidence, demographic features, and clinical characteristics. Arch Ophthalmol 121:1392\u20131396. https:\/\/doi.org\/10.1001\/archopht.121.10.1392","journal-title":"Arch Ophthalmol"},{"key":"4924_CR3","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/j.ophtha.2014.06.016","volume":"121","author":"Y Li","year":"2014","unstructured":"Li Y, You QS, Wei WB, Xu J, Chen CX, Wang YX, Xu L, Jonas JB (2014) Polypoidal choroidal vasculopathy in adult Chinese: the Beijing eye study. Ophthalmology 121:2290\u20132291. https:\/\/doi.org\/10.1016\/j.ophtha.2014.06.016","journal-title":"Ophthalmology"},{"key":"4924_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"4924_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik J-F, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"4924_CR6","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897\u20131908. https:\/\/doi.org\/10.1056\/NEJMoa1102673","journal-title":"N Engl J Med"},{"key":"4924_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","volume":"143","author":"AE Fung","year":"2007","unstructured":"Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566\u2013583.e562. https:\/\/doi.org\/10.1016\/j.ajo.2007.01.028","journal-title":"Am J Ophthalmol"},{"key":"4924_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.oret.2019.04.018","volume":"3","author":"GT Kokame","year":"2019","unstructured":"Kokame GT, deCarlo TE, Kaneko KN, Omizo JN, Lian R (2019) Anti\u2013vascular endothelial growth factor resistance in exudative macular degeneration and polypoidal choroidal vasculopathy. Ophthalmol Retina 3:744\u2013752. https:\/\/doi.org\/10.1016\/j.oret.2019.04.018","journal-title":"Ophthalmol Retina"},{"key":"4924_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ajo.2009.02.012","volume":"148","author":"M Cho","year":"2009","unstructured":"Cho M, Barbazetto IA, Freund KB (2009) Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 148:70\u201378.e71. https:\/\/doi.org\/10.1016\/j.ajo.2009.02.012","journal-title":"Am J Ophthalmol"},{"key":"4924_CR10","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen L-J, Chen S-J, Hashad Y, Kim H, Lai TY, Pilz S, Ruamviboonsuk P, Tokaji E (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32:1453\u20131464","journal-title":"Retina"},{"key":"4924_CR11","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127:616\u2013636","journal-title":"Ophthalmology"},{"key":"4924_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-47738-9","volume":"9","author":"N Nagai","year":"2019","unstructured":"Nagai N, Suzuki M, Minami S, Kurihara T, Kamoshita M, Sonobe H, Watanabe K, Uchida A, Shinoda H, Tsubota K, Ozawa Y (2019) Dynamic changes in choroidal conditions during anti-vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Sci Rep 9:1\u20139","journal-title":"Sci Rep"},{"key":"4924_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.survophthal.2013.03.009","volume":"59","author":"RP Finger","year":"2014","unstructured":"Finger RP, Wickremasinghe SS, Baird PN, Guymer RH (2014) Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol 59:1\u201318. https:\/\/doi.org\/10.1016\/j.survophthal.2013.03.009","journal-title":"Surv Ophthalmol"},{"key":"4924_CR14","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","volume":"122","author":"Y Kuroda","year":"2015","unstructured":"Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N (2015) Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study. Ophthalmology 122:2303\u20132310. https:\/\/doi.org\/10.1016\/j.ophtha.2015.06.053","journal-title":"Ophthalmology"},{"key":"4924_CR15","doi-asserted-by":"publisher","unstructured":"Kong M, Kim SM, Ham DI (2017) Comparison of clinical features and 3-month treatment response among three different choroidal thickness groups in polypoidal choroidal vasculopathy. PLoS One 12. https:\/\/doi.org\/10.1371\/journal.pone.0184058","DOI":"10.1371\/journal.pone.0184058"},{"key":"4924_CR16","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1097\/IAE.0000000000001427","volume":"37","author":"Y Sakurada","year":"2017","unstructured":"Sakurada Y, Sugiyama A, Tanabe N, Kikushima W, Kume A, Iijima H (2017) Choroidal thickness as a prognostic factor of photodynamic therapy with aflibercept or ranibizumab for polypoidal choroidal vasculopathy. Retina 37:1866\u20131872. https:\/\/doi.org\/10.1097\/IAE.0000000000001427","journal-title":"Retina"},{"key":"4924_CR17","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1007\/s00417-015-3221-x","volume":"254","author":"H Kim","year":"2016","unstructured":"Kim H, Lee SC, Kwon KY, Lee JH, Koh HJ, Byeon SH, Kim SS, Kim M, Lee CS (2016) Subfoveal choroidal thickness as a predictor of treatment response to anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 254:1497\u20131503. https:\/\/doi.org\/10.1007\/s00417-015-3221-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4924_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ajo.2016.03.024","volume":"166","author":"M Suzuki","year":"2016","unstructured":"Suzuki M, Nagai N, Shinoda H, Uchida A, Kurihara T, Tomita Y, Kamoshita M, Iyama C, Tsubota K, Ozawa Y (2016) Distinct responsiveness to intravitreal ranibizumab therapy in polypoidal choroidal vasculopathy with single or multiple polyps. Am J Ophthalmol 166:52\u201359. https:\/\/doi.org\/10.1016\/j.ajo.2016.03.024","journal-title":"Am J Ophthalmol"},{"key":"4924_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/srep44020","volume-title":"Scientific Reports","author":"W Kikushima","year":"2017","unstructured":"Kikushima W, Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kume A, Mabuchi F, Iijima H (2017) Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration. In: Scientific Reports, p 7. https:\/\/doi.org\/10.1038\/srep44020"},{"key":"4924_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1007\/s00417-015-3241-6","volume":"254","author":"HM Kang","year":"2016","unstructured":"Kang HM, Koh HJ, Lee SC (2016) Baseline polyp size as a potential predictive factor for recurrence of polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 254:1519\u20131527. https:\/\/doi.org\/10.1007\/s00417-015-3241-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4924_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10384-014-0349-x","volume":"59","author":"HJ Cho","year":"2015","unstructured":"Cho HJ, Han SY, Kim HS, Lee TG, Kim JW (2015) Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 59:29\u201335. https:\/\/doi.org\/10.1007\/s10384-014-0349-x","journal-title":"Jpn J Ophthalmol"},{"key":"4924_CR22","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1097\/IAE.0000000000001451","volume":"37","author":"T Wakazono","year":"2017","unstructured":"Wakazono T, Yamashiro K, Oishi A, Ooto S, Tamura H, Akagi-Kurashige Y, Hata M, Takahashi A, Tsujikawa A, Yoshimura N (2017) Recurrence of choroidal neovascularization lesion activity after aflibercept treatment for age-related macular degeneration. Retina 37:2062\u20132068. https:\/\/doi.org\/10.1097\/IAE.0000000000001451","journal-title":"Retina"},{"key":"4924_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1089\/jop.2017.0013","volume":"33","author":"GD Fliney","year":"2017","unstructured":"Fliney GD, Zukin LM, Hagedorn C (2017) Neovascular age-related macular degeneration disease quiescence with visual acuity stability in a subgroup of patients following PRN treatment. J Ocul Pharmacol Ther 33:604\u2013609. https:\/\/doi.org\/10.1089\/jop.2017.0013","journal-title":"J Ocul Pharmacol Ther"},{"key":"4924_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","volume":"156","author":"HM Kang","year":"2013","unstructured":"Kang HM, Koh HJ (2013) Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol 156:652\u2013660. https:\/\/doi.org\/10.1016\/j.ajo.2013.05.038","journal-title":"Am J Ophthalmol"},{"key":"4924_CR25","doi-asserted-by":"publisher","unstructured":"Kokame GT, Lai JC, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K (2016) Prospective clinical trial of intravitreal aflibercept treatment for polypoidal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results. BMC Ophthalmol 16. https:\/\/doi.org\/10.1186\/s12886-016-0305-2","DOI":"10.1186\/s12886-016-0305-2"},{"key":"4924_CR26","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ajo.2015.01.018","volume":"159","author":"A Oishi","year":"2015","unstructured":"Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, Ueda-Arakawa N, Miyake M, Akagi-Kurashige Y, Hata M, Yoshikawa M, Kuroda Y, Takahashi A, Yoshimura N (2015) One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol 159:853\u2013860.e851. https:\/\/doi.org\/10.1016\/j.ajo.2015.01.018","journal-title":"Am J Ophthalmol"},{"key":"4924_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1159\/000458538","volume":"237","author":"A Yamamoto","year":"2017","unstructured":"Yamamoto A, Okada AA, Nakayama M, Yoshida Y, Kobayashi H (2017) One-year outcomes of a treat-and-extend regimen of aflibercept for exudative age-related macular degeneration. Ophthalmologica 237:139\u2013144. https:\/\/doi.org\/10.1159\/000458538","journal-title":"Ophthalmologica"},{"key":"4924_CR28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/eye.2015.80","volume":"29","author":"L Kuehlewein","year":"2015","unstructured":"Kuehlewein L, Sadda SR, Sarraf D (2015) OCT angiography and sequential quantitative analysis of type 2 neovascularization after ranibizumab therapy. Eye (Basingstoke) 29:932\u2013935. https:\/\/doi.org\/10.1038\/eye.2015.80","journal-title":"Eye (Basingstoke)"},{"key":"4924_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1159\/000433547","volume":"54","author":"G Coscas","year":"2015","unstructured":"Coscas G, Lupidi M, Coscas F, Fran\u00e7ais C, Cagini C, Souied EH (2015) Optical coherence tomography angiography during follow-up: qualitative and quantitative analysis of mixed type I and II choroidal neovascularization after vascular endothelial growth factor trap therapy. Ophthalmic Res 54:57\u201363. https:\/\/doi.org\/10.1159\/000433547","journal-title":"Ophthalmic Res"},{"key":"4924_CR30","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1097\/IAE.0000000000001391","volume":"37","author":"CMG Cheung","year":"2017","unstructured":"Cheung CMG, Yanagi Y, Mohla A, Lee SY, Mathur R, Chan CM, Yeo I, Wong TY (2017) Characterization and differentiation of polypoidal choroidal vasculopathy using swept source optical coherence tomography angiography. Retina 37:1464\u20131474. https:\/\/doi.org\/10.1097\/IAE.0000000000001391","journal-title":"Retina"},{"key":"4924_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/IAE.0b013e3182657fff","volume":"33","author":"N Lois","year":"2013","unstructured":"Lois N, McBain V, Abdelkader E, Scott N, Kumari R (2013) Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy. Retina 33:13\u201322. https:\/\/doi.org\/10.1097\/IAE.0b013e3182657fff","journal-title":"Retina"},{"key":"4924_CR32","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","volume":"36","author":"NS Abdelfattah","year":"2016","unstructured":"Abdelfattah NS, Zhang H, Boyer DS, Sadda SR (2016) Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina 36:1843\u20131850. https:\/\/doi.org\/10.1097\/IAE.0000000000001059","journal-title":"Retina"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-020-04924-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-020-04924-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T14:07:20Z","timestamp":1617286040000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-020-04924-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4924"],"URL":"https:\/\/doi.org\/10.1007\/s00417-020-04924-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"10 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Approval was granted by the Institutional Review Board (IRB) at Severance Hospital prior to study initiation. Patient consent was waived by the IRB committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}